Navigation Links
Genetic Mutations Linked to Deadly Brain Cancer
Date:2/18/2009

Tests could one day individualize treatment, researcher says

WEDNESDAY, Feb. 18 (HealthDay News) -- Researchers report that they've discovered two genetic mutations that play an important role in the development of some particularly dangerous types of brain tumors.

The findings "open a completely new avenue" to better treatments for one of the most deadly forms of cancer, said Dr. Hai Yan, lead author of a study published in the Feb. 19 issue of the New England Journal of Medicine.

For the moment, the research doesn't appear likely to result in immediate benefits for patients. But ultimately, it may allow physicians to "understand what kind of tumor patients have and give them the right treatment," said Yan, an assistant professor of pathology at Duke University, in Durham, N.C.

At issue are brain tumors known as gliomas. About 10,000 Americans are diagnosed with the tumors each year -- the most famous current patient is Senator Edward Kennedy -- and the prognosis is grim. While the cancer typically doesn't spread to other parts of the body, it can create havoc in the brain and cause death within months.

The tumors are hard to treat. Chemotherapy and radiation can damage healthy brain tissue and only allow patients to live a few months longer. The only effective drug appears to extend lifespan for just a couple of months, Yan said.

Surgery is an option, but "gliomas generally spread in the brain the way roots spread from a plant," Yan said. "It is very difficult to completely remove the tumors."

In the new study, Yan and colleagues found that two genetic mutations appear in more than 70 percent of certain kinds of these tumors.

"You could use these genes to distinguish a subtype of glioma," Yan said. "Two tumors may look like a duck and walk like a duck, but the two tumors may be quite different."

Once a test determines the type of a glioma in a patient, doctors could conceivably choose from an array of treatments. "You can give one kind of patients one kind of drug, and others another kind of drug," Yan said.

That kind of tailored treatment awaits on the horizon. But for the time being, a genetic test that costs less than $100 could provide information to patients about their prognosis by revealing the type of tumor they have, Yan said.

The results are promising because they reveal that there two distinct types of tumor, said Dr. Craig Thompson, chairman of the University of Pennsylvania's Department of Cancer Biology and Medicine.

"They are caused by different mutations and therefore are likely to respond to different therapies," said Thompson, who wrote a commentary accompanying the study. "Before this, we did not know what caused these tumors."

More information

Learn more about brain cancer from the National Institutes of Health.



SOURCES: Hai Yan, M.D., Ph.D., assistant professor, Department of Pathology, Duke University, Durham, N.C.; Craig Thompson, M.D., chairman, Department of Cancer Biology and Medicine, University of Pennsylvania, Philadelphia; Feb. 19, 2009, New England Journal of Medicine


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Genetics May Help Fine-Tune Warfarin Dosage
2. Exploring Genetic Link Between Migraines, Cardiovascular Trouble
3. Researchers identify novel genetic markers linked to increased risk of heart attack
4. Genetic Code of Common Cold Cracked
5. Study: Genetic Risk for Substance Use Can be Neutralized by Good Parenting
6. Study: Genetic risk for substance use can be neutralized by good parenting
7. BioInformatics, LLC, A Recognized Sponsor of First Annual Consumer Genetics Show in Boston, June 9-11, 2009
8. Genetic Test for Heart Disease Risk in the Works
9. ANA and ISONG Co-Publish Genetics and Ethics in Health Care: New Questions in the Age of Genomic Health
10. American College of Medical Genetics Foundation Unveils New Website: ACMG Foundation Supports Medical Genetics Research, Education and Practice
11. Interleukin Genetics to Present at G-2 Reports Molecular Diagnostic Conference
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Genetic Mutations Linked to Deadly Brain Cancer
(Date:3/24/2017)... ... March 24, 2017 , ... Shamanic healer and teacher Anahata ... and Spiritual Awakening, proudly presents her Sacred Peru retreat with world famous ... spiritual journey during the Summer Solstice will also be her final international retreat, ...
(Date:3/24/2017)... ... March 24, 2017 , ... As the standards bearer ... communications platform that positions them as the go-to thought leader in all matters ... publication as an always-on, always-fresh news, views and advocacy engine, called ONS Voice. ...
(Date:3/24/2017)... CA (PRWEB) , ... March 24, 2017 , ... ... on two panels at the Advanced ERISA Benefit Claims Litigation seminar in Chicago, ... Creating the Administrative Record, The majority of cases litigated under ERISA involve claims ...
(Date:3/24/2017)... ... 2017 , ... Viewers who like to educate themselves on current issues and ... services, and societal issues tend to appreciate and love the "Informed" series, hosted by ... running events for causes around the world. , Running for charity has ...
(Date:3/24/2017)... Southlake, Texas (PRWEB) , ... March 24, 2017 ... ... make 2017 the year of enhancements, upgrading their training and leads programs. , ... Empower University. Reserved for elite sales agents, Performance Partners is designed to teach ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... 23, 2017  A new genetic test has ... of individuals who carry HLA-B*15:02 and ... yet potentially deadly side effect of certain medications ... gene HLA-B*15:02 is strongly associated with ... syndrome and toxic epidermal necrolysis in patients treated ...
(Date:3/23/2017)... Prima BioMed has presented encouraging early signs ... combination with Keytruda, with one of the six melanoma ... response. Recruitment in the second cohort is complete and ... by Q317. Preliminary efficacy data from the 15-patient, run-in ... mid-year (recruitment in the 226-patient Phase IIb component is ...
(Date:3/23/2017)... New York , March 23, 2017 /PRNewswire/ ... market exhibits a consolidated vendor landscape with the top ... overall market in 2015. These companies are Stryker ... Inc., Hygia Health Services, Inc., and VANGUARD AG. ... reprocessed medical devices market is witnessing the prevalence ...
Breaking Medicine Technology: